SELECT PUBLICATIONS
Andre T et al; MOSAIC Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51. Abstract
Benson AB 3rd et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22(16):3408-19.
Abstract
De Gramont A et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy
results of the MOSAIC trial, including survival, with a median follow-up of six years.
Proc ASCO 2007;Abstract 4007.
Gill S et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and
III colon cancer: Who benefits and by how much? J Clin Oncol 2004;22(10):1797-806.
Abstract
Gray RG et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. Proc ASCO 2004;Abstract 3501.
Grothey A, Sargent DJ. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. J Clin Oncol 2005;23(15):3311-3. No abstract available
O’Connell MJ et al. Survival following recurrence in patients with adjuvant colon cancer:
Findings from the 20,800-patient ACCENT dataset. Proc ASCO 2007;Abstract 4009.
Sargent DJ et al. Time-dependent patterns of failure and treatment benefit from adjuvant
therapy for resectable colon cancer: Lessons from the 20,800-patient (pt) ACCENT dataset. Proc ASCO 2007;Abstract 4008.
Sargent DJ et al. Disease-free survival versus overall survival as a primary end point
for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18
randomized trials. J Clin Oncol 2005;23(34):8664-70. Abstract
